The simulation provided an opportunity for meeting attendees to observe the process by which oncologists determine initial diagnostic tests critical to treatment selection, the most appropriate treatment for each line of therapy, and criteria for subsequent treatment selection.
Shape Change at Every Step
The implementation of evidence-based treatment strategies has improved cost savings and supported value-based care models across three distinct oncology practices within Cedars-Sinai Medical Center.
The ICER has released a scoping document that will compare the clinical effectiveness and value of multiple CAR-T cell treatments under review by the FDA.
This paper explores the growing trend of clinical pathways for symptom management—including how they can be applied across cancer care and the positive downstream effects of pathways for symptom control—by examining the implementation of symptom management clinical pathways at one treatment center.
A precision medicine support tool helps oncologists make clinical decisions and enroll patients in genotype-matched trials based on actionable mutations.
Rationale for the Development of Clinical Pathways and an Overview of the Clinical Pathways Office at the Seattle Cancer Care Alliance
This paper examines the establishment of the Seattle Cancer Care Alliance Clinical Pathways Office, as well as the goals of clinical pathway development from the standpoint of a regional hospital system.
Approximately 170 million covered lives in oncology are potentially impacted by clinical pathways, representing 57% of the patient population. The American Society of Clinical Oncology (ASCO) has taken notice, and has actively participated in the conversation surrounding clinical pathways.
Biosimilars occupy a huge place in the oncology treatment conversation these days. But what are they exactly, and how will they impact clinical pathways?